Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutationsHiromichi Ebi, Isao Oze, Takayuki Nakagawa, et al.
Cancer Science|May 1, 2021
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancerHiroya Taniguchi, Yoshiaki Nakamura, Daisuke Kotani, et al.
Communications Biology|June 25, 2021
TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancersFumie Nakasuka, Sho Tabata, Takeharu Sakamoto, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal CancerRona Yaeger, Daisuke Kotani, Sebastián Mondaca, et al.
ESMO Open|February 8, 2021
BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancerDaisuke Kotani, Hideaki Bando, Hiroya Taniguchi, et al.
Cancers|June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXACarter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
NPJ Precision Oncology|December 15, 2023
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibitionXianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, et al.
Cell Reports|July 29, 2022
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibitionJinyang Cai, Sheeba Jacob, Richard Kurupi, et al.
Pageof 8